Objective:

To evaluate the preliminary clinical application value of MAMMI dedicated breast PET.

Methods:

A total of 76 patients with positive breast lesions on whole-body

18

F-fluorodeoxyglucose (18F-FDG) PET/CT or suspicious occult breast cancer voluntarily underwent MAMMI PET in prone position after whole-body

18

F-FDG PET/CT. The maximal standardized uptake values (SUVmax) were compared according to lesion size

ultrasound grading and molecular subtype of breast cancer.

Results:

MAMMI PET visualized 63 lesions in 48 patients with specific pathologic diagnosis. The smallest lesion was 0.3 cm indiameter. Malig

nant lesions were classified into 3 groups based on diameter as follows: grade 1

1 cm or smaller; grade 2

1 to 2 cm; and grad 3

larger than 2 cm. The mean values of SUVmax of them were 4.58 2.01

7.51 3.10 and 11.275.29

respectively

and there were significant differences in SUVmax through pairwise comparison (

P

0.01 or

P

0.05). Difference in SUVmax was also observed between Breast Imaging Reporting and Data System (BI-RADS) grade 4 and grade 5 (

P

0.05). But there were no significant differences among different molecular subtypes.

Conclusion:

MAMMI PET has a promising clinical value in detecting small

multicenter and multiple primary breast lesions.